Despite a move away from chemotherapy for many solid organ cancers, cytotoxic regimens remain the standard of care for patients with metastatic pancreatic cancer. However, frequently used regimens only modestly improve survival, are associated with considerable toxicity, and cause treatment resistance in many patients early on. Investigators are focusing on approaches for improving the tolerability to cytotoxic agents and on identifying novel anticancer therapies that may lead to long-term survival, if not cure, with minimal toxicity.
Read more . . .